Manager Investor RelationsWe currently do not have informatin regarding Antje Zeise. This executive tanure with Epigenomics AG is not currenlty determined.
49 30 243 450 http://www.epigenomics.de
The company has return on total asset (ROA)
of (25.16) %
which means that it has lost $25.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (70.57) %
meaning that it generated substantial loss on money invested by shareholders.
Epigenomics AG, a molecular diagnostics company, engages in developing and commercializing a pipeline of proprietary solutions for screening and diagnosis of cancer in Europe, North America, and internationally. Epigenomics AG [EPGNF] is a Pink Sheet
which is traded through a dealer network over-the-counter (OTC).